External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

AAMDSIF 2025

-
Coming soon
06:00 PM
Duration 90mins Maryland, USA
Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab▼ in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched From Eculizumab
Phillip Scheinberg, Diego Villa Clé, Berangere Devalet, Valentina Giai, Cristina Barrenetxea Lekue, Hsuan-Yu Lin, Zsolt Nagy, Jun-ichi Nishimura, Jens Panse, Agnieszka Piekarska, Jorg Schubert, Kazutaka Sunam, Mustafa N. Yenerel, Anita Appius, Brittany Gentile, Shino Iwase, Himika Patel, Sasha Sreckovic, Austin G Kulasekararaj

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins Maryland, USA
Phase III Randomized COMMODORE 2 Trial: 2-Year Efficacy and Safety of Crovalimab▼ in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Naive to Complement Inhibition
Phillip Scheinberg, Alexander Röth, Guangsheng He, Andres Brodsky, Chatree Chai-Adisaksopha, Narcisa Sonia Comia, Anna Gaya, Martin Höglund, Richard J Kelly, Ahlam Naila Kori, Je-Hwan Lee, Naoshi Obara, Antonio Risitano, Anita Appius, Leigh Beveridge, Brittany Gentile, Sasha Sreckovic, Zilu Zhang, Bing Han

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins Maryland, USA
Phase III COMMODORE 1 Trial: 2-Year Efficacy and Safety of Crovalimab▼ (Crova) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Ravulizumab (Ravu)
Phillip Scheinberg, Hazzaa Alzahrani, Alejandro Contento Gonzalo, Martin Höglund, Jin Seok Kim, Jens Panse, Melissa J Rose, Jorg Schubert, Yasutaka Ueda, Eng Soo Yap, Muriel Buri, Nicolo Compagno, Brittany Gentile, Sasha Sreckovic, Austin G Kulasekararaj

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar